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Chronic neuropathic pain is a huge problem to the health and well-being of an 
increasingly ageing population in the US, as substantiated by the large unmet 
clinical need associated with this type of pain, with estimates of 30-50% of 
sufferers refractory to existing medication.  Thus, there is an imperative to 
increase knowledge of mechanisms of action of the key proteins in nociceptive 
pathways in vitro and to extend this knowledge to in vivo models of neuropathy to 
advance therapeutic development in this area.  N-type voltage-gated Ca2+ 
channels (CaV2.2) have emerged as potential novel targets for the treatment of 
chronic neuropathic pain.  Funded, in part, by a FORCES grant, we have 
identified two novel derivatives of the parent 15 amino acid CBD3 peptide, 
derived from collapsin response mediator protein 2 (CRMP-2) that suppressed 
inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to N-
type voltage gated calcium channels (CaV2.2) [Brittain et al., Nature Medicine 
17:822-829 (2011)].  Pharmacokinetic studies revealed nanogram levels of 
peptide in plasma of rats systemic administration consistent with relief of 
hypersensitivity.  Furthermore, we observed improved and broader efficacy of the 
derivatized peptides in AIDS-therapy and nerve-injury related neuropathic pain 
models.  Future studies regarding dosing and route of delivery optimization as 
well as identification of peptide-mimetics are ongoing to fully realize the 
commercial value of the peptides.  Supported by the Startup program at the 
Indiana University Research & Technology Corporation (IURTC), we have setup 
Sophia Therapeutics LLC and together with IURTC are committed to the work 
proposed here.    
